Inclusion Criteria:

- Male or female, 18 years of age or older

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Histologically or cytologically confirmed, Stage IV non-squamous NSCLC

- No prior treatment for Stage IV non-squamous NSCLC. Participants with a sensitizing
mutation in the epidermal growth factor receptor (EGFR) gene or with an anaplastic
lymphoma kinase (ALK) fusion oncogene are excluded.

- Participants who have received prior neo-adjuvant, adjuvant chemotherapy, or
chemoradiotherapy with curative intent for non-metastatic disease must have
experienced a treatment-free interval of at least 6 months from randomization since
the last chemotherapy or completion of chemoradiotherapy

- Known programmed death-ligand 1 (PD-L1) tumor status as determined by an
immunohistochemistry (IHC) assay performed by a central laboratory on previously
obtained archival tumor tissue or tissue obtained from a biopsy at screening

- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors
Version 1.1 (RECIST v1.1)

- Adequate hematologic and end organ function

- For women of childbearing potential: agreement to remain abstinent or use
contraceptive methods that result in a failure rate of less than (<) 1 percent (%)
per year during the treatment period and for at least 90 days after the last dose of
study treatment

- For men: agreement to remain abstinent or use contraceptive measures and agreement to
refrain from donating sperm

Exclusion Criteria:

Cancer-Specific Exclusions

- Active or untreated central nervous system (CNS) metastases as determined by computed
tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and
prior radiographic assessments

- Spinal cord compression not definitively treated with surgery and/or radiation or
previously diagnosed and treated spinal cord compression without evidence that
disease has been clinically stable for >= 2 weeks prior to randomization

- Leptomeningeal disease

- Uncontrolled tumor-related pain

- Uncontrolled or symptomatic hypercalcemia (greater than [>] 1.5 millimole/Liter
ionized calcium or calcium > 12 milligram/deciliter or corrected serum calcium >upper
limit of normal)

- Malignancies other than NSCLC within 5 years prior to randomization

- Known tumor PD-L1 expression status from other clinical studies (e.g., participants
whose PD-L1 expression status was determined during screening for entry into a study
with anti-PD-1 or anti-PD L1 antibodies but were not eligible are excluded)

General Medical Exclusions:

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins

- History of certain autoimmune disease

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis

- Severe infections within 4 weeks prior to randomization

- Significant cardiovascular disease, such as New York Heart Association cardiac
disease (Class II or greater), myocardial infarction within 3 months prior to
randomization, unstable arrhythmias, or unstable angina

Exclusion Criteria Related to Medications and Chemotherapy:

- Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within
3 weeks prior to initiation of study treatment

- Prior treatment with CD137 agonists or immune checkpoint blockade therapies,
anti-PD-1, and anti-PD-L1 therapeutic antibodies

- Treatment with systemic immunostimulatory agents within 4 weeks prior to
randomization

- Treatment with systemic immunosuppressive medications

Exclusion Criteria Related to Chemotherapy:

- History of allergic reactions to cisplatin, carboplatin, or other platinum-containing
compounds

- Participants with hearing impairment (cisplatin)

- Grade >= 2 peripheral neuropathy as defined by National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria (cisplatin)

- Creatinine clearance (CRCL) =< 60 milliliter (mL)/minute (min) for cisplatin or < 45
mL/min for carboplatin

Minimum Eligible Age: 18 Years

Maximum Eligible Age: N/A

Eligible Gender: Both